晚期胃食管癌免疫与靶向治疗:ASCO指南更新
指南强调可操作生物标志物(PD-L1、CLDN18.2、HER2、MMR/MSI)应尽早检测以指导治疗决策,并分层给出免疫联合化疗、靶向治疗及后线选择的具体推荐。
要点
- pMMR/MSS且HER2阴性、PD-L1≥1的胃食管腺癌或鳞癌,推荐免疫联合双药化疗。
- 胃食管腺癌PD-L1<1且CLDN18.2阳性者推荐唑贝妥昔单抗;双阳性需共同决策。
- dMMR/MSI-H胃食管癌推荐单用免疫或联合双药化疗。
核心结论
- 晚期胃食管癌治疗需基于PD-L1、CLDN18.2、HER2及MMR/MSI状态分层选择免疫或靶向方案。
研究设计与样本
- ASCO专家组召开会议,对相关研究进行系统综述并制定临床实践推荐。
主要发现
- pMMR/MSS、HER2阴性、PD-L1≥1的胃食管腺癌或鳞癌患者,PD-L1表达更高者更可能从免疫治疗获益。
- pMMR/MSS、HER2阳性胃/胃食管交界腺癌推荐曲妥珠单抗联合双药化疗;PD-L1≥1者加用帕博利珠单抗。
- dMMR/MSI-H胃食管癌推荐单用免疫治疗或免疫联合双药化疗。
关键数值与推荐
- 推荐目标人群为不可切除局部晚期、晚期或转移性胃食管癌患者。
- 可操作生物标志物检测结果应尽快获得,以指导治疗决策。
- 胃食管腺癌、PD-L1<1且CLDN18.2阳性者推荐唑贝妥昔单抗。
- PD-L1与CLDN18.2双阳性患者应结合指南所列因素进行共同决策。
- 无可操作生物标志物阳性或不适合靶向/免疫治疗者,推荐单用双药化疗。
临床怎么用
- 治疗前应尽快完成PD-L1、CLDN18.2、HER2及MMR/MSI检测,依据结果分层选择方案。
- 二线治疗可选雷莫西尤单抗联合紫杉醇、HER2阳性胃/GEJ腺癌用德曲妥珠单抗、PD-L1≥1食管鳞癌一线未用免疫者用免疫治疗。
- PD-L1与CLDN18.2双阳性患者需与患者共同决策,权衡指南所述因素。
局限性
- 指南为自愿使用,需结合独立专业判断,不适用于所有患者、干预、疾病或分期。
- 指南基于文献综述与分析,不构成标准治疗声明,ASCO不认可第三方药物、设备、服务或疗法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual. ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines.Clinical Practice Guidelines and other guidance ("Guidance") provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases, or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more. PURPOSE: To provide updated recommendations for immunotherapy and targeted therapy for patients with advanced gastroesophageal cancer. METHODS: ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice. RESULTS: Twelve newly published or updated phase III randomized controlled trials met the inclusion criteria for the systematic review. RECOMMENDATIONS: The target population for these recommendations is patients with unresectable locally advanced, advanced, or metastatic gastroesophageal cancer. Results from testing for actionable biomarkers should be available as soon as possible to inform treatment decision making. Immunotherapy with doublet chemotherapy is recommended for patients with proficient mismatch repair (pMMR)/microsatellite stable (MSS) human epidermal growth factor receptor 2 (HER2)-negative gastroesophageal adenocarcinoma or squamous cell carcinoma and PD-L1 expression ≥1; patients with higher PD-L1 expression are more likely to benefit from immunotherapy. Zolbetuximab is recommended for patients with gastroesophageal adenocarcinoma, PD-L1 <1, and positive CLDN18.2 expression. Patients with dual PD-L1 and CLDN18.2 positivity should engage in shared decision making, considering the factors outlined in the guideline. Doublet chemotherapy alone is recommended for patients who are not positive for actionable biomarkers or are not considered candidates for targeted therapy or immunotherapy. For patients with pMMR/MSS HER2-positive gastric/gastroesophageal junction (GEJ) adenocarcinoma, trastuzumab and doublet chemotherapy is recommended; for patients with PD-L1 expression ≥1, the addition of pembrolizumab is recommended. Immunotherapy alone or with doublet chemotherapy is recommended for patients with mismatch repair deficient/microsatellite instability-high gastroesophageal cancer. Second-line therapy options include ramucirumab with paclitaxel, trastuzumab deruxtecan for HER2-positive gastric/GEJ adenocarcinoma, and immunotherapy for PD-L1 ≥1 esophageal squamous cell carcinoma after first-line combination chemotherapy without immunotherapy.Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.
引用
- Shah MA, Kennedy EB, Deighton D, et al. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update. J Clin Oncol. 2026. PMID: 41747202. doi:10.1200/JCO-25-02958
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。